Abbott: Peripheral Artery Disease Treatment Receives Breakthrough Designation
August 27, 2025
August 27, 2025
WASHINGTON, Aug. 27 -- Abbott has received CE Mark approval in Europe for its Esprit BTK Everolimus Eluting Resorbable Scaffold System, an innovation designed to treat peripheral artery disease (PAD) below the knee.
According to the Abbott Park, Illinois company, the device works by delivering a drug to the vessel wall before gradually dissolving, a method that is an alternative to the standard balloon angioplasty procedure.
The company said on August 25, 2025, that app . . .
According to the Abbott Park, Illinois company, the device works by delivering a drug to the vessel wall before gradually dissolving, a method that is an alternative to the standard balloon angioplasty procedure.
The company said on August 25, 2025, that app . . .